CHRISTINE BEETON to Lymphocyte Activation
This is a "connection" page, showing publications CHRISTINE BEETON has written about Lymphocyte Activation.
Connection Strength
0.318
-
Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm Allergy Drug Targets. 2011 Oct; 10(5):313-21.
Score: 0.082
-
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81.
Score: 0.052
-
[Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers]. Rev Neurol (Paris). 2004 May; 160(5 Pt 2):S16-27.
Score: 0.049
-
Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001 Jan 15; 166(2):936-44.
Score: 0.039
-
A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Sci Rep. 2014 Mar 28; 4:4509.
Score: 0.024
-
Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012 Sep; 82(3):372-82.
Score: 0.022
-
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 2012 Mar 15; 59(4):529-46.
Score: 0.020
-
Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17; 29(4):602-14.
Score: 0.017
-
Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003 Sep; 6(5):640-7.
Score: 0.012